文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

乌干达非B亚型HIV-1拉替拉韦治疗失败者整合酶抑制剂耐药突变累积导致多替拉韦高水平耐药

Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

研究纳入乌干达51例拉替拉韦为基础的三线治疗失败的非B亚型HIV-1感染者,用Sanger和深度测序检测整合酶耐药突变,并对13例患者整合酶基因进行克隆,测定复制能力及对多替拉韦、拉替拉韦和埃替拉韦的表型敏感性。47%患者检出整合酶耐药突变;携带单个原发突变(N155H或Y143R/S)的重组病毒对多替拉韦敏感,但对拉替拉韦和埃替拉韦高度耐药(>50倍变化);两例多重突变患者对拉替拉韦、埃替拉韦甚至多替拉韦显示最高耐药。提示长期拉替拉韦暴露下多重耐药突变累积可导致包括多替拉韦在内的整合酶抑制剂高水平耐药,LMICs或需更常规的整合酶抑制剂治疗监测。

要点

  • 拉替拉韦失败者中47%检出整合酶耐药突变
  • 单个原发突变对多替拉韦敏感但对拉替拉韦/埃替拉韦高度耐药
  • 多重突变累积可导致多替拉韦耐药

核心结论

  • 在拉替拉韦治疗失败的HIV-1 A和D亚型感染者中,携带整合酶耐药突变者对埃替拉韦和拉替拉韦呈高水平耐药。
  • 长期拉替拉韦暴露伴病毒学失败期间多重整合酶耐药突变累积,可导致包括多替拉韦耐药在内的高水平整合酶抑制剂耐药。

研究设计与样本

  • 研究初始选择51例在乌干达接受以拉替拉韦为基础的三线治疗失败的非B亚型HIV-1感染者。
  • 用Sanger和深度测序检测耐药突变,对13例患者整合酶基因克隆,用TZM-bl细胞测定复制能力和对多替拉韦、拉替拉韦、埃替拉韦的表型敏感性。
  • 用Spearman相关系数分析整合酶抑制剂间交叉耐药。

主要发现

  • 47%患者检出整合酶耐药突变。
  • 携带单个原发整合酶耐药突变(N155H或Y143R/S)的HIV整合酶重组病毒对多替拉韦敏感,但对拉替拉韦和埃替拉韦高度耐药(>50倍变化)。
  • 一例携带E138A/G140A/Q148R/G163R、一例携带E138K/G140A/S147G/Q148K的患者对拉替拉韦、埃替拉韦甚至多替拉韦显示最高耐药。
  • 前者多重耐药病毒复制能力为野生型,后者复制能力低于野生型。

临床怎么用

  • 对长期拉替拉韦暴露且病毒学失败者应警惕多重整合酶耐药突变累积及多替拉韦耐药可能。
  • LMICs可考虑更常规的整合酶抑制剂治疗监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing first-line treatment failures in low- and middle-income countries (LMICs) have led to increased use of integrase strand transfer inhibitors (INSTIs) such as dolutegravir. However, HIV-1 susceptibility to INSTIs in LMICs, especially with previous raltegravir exposure, is poorly understood due to infrequent reporting of INSTI failures and testing for INSTI drug resistance mutations (DRMs). METHODS: A total of 51 non-subtype B HIV-1 infected patients failing third-line (raltegravir-based) therapy in Uganda were initially selected for the study. DRMs were detected using Sanger and deep sequencing. HIV integrase genes of 13 patients were cloned and replication capacities (RCs) and phenotypic susceptibilities to dolutegravir, raltegravir and elvitegravir were determined with TZM-bl cells. Spearman's correlation coefficient was used to determine cross-resistance between INSTIs. RESULTS: INSTI DRMs were detected in 47% of patients. HIV integrase-recombinant virus carrying one primary INSTI DRM (N155H or Y143R/S) was susceptible to dolutegravir but highly resistant to raltegravir and elvitegravir (>50-fold change). Two patients, one with E138A/G140A/Q148R/G163R and one with E138K/G140A/S147G/Q148K, displayed the highest reported resistance to raltegravir, elvitegravir and even dolutegravir. The former multi-DRM virus had WT RC whereas the latter had lower RCs than WT. CONCLUSIONS: In HIV-1 subtype A- and D-infected patients failing raltegravir and harbouring INSTI DRMs, there is high-level resistance to elvitegravir and raltegravir. More routine monitoring of INSTI treatment may be advised in LMICs, considering that multiple INSTI DRMs may have accumulated during prolonged exposure to raltegravir during virological failure, leading to high-level INSTI resistance, including dolutegravir resistance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ndashimye E, Avino M, Olabode AS, et al. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda. J Antimicrob Chemother. 2020. PMID: 32853364. doi:10.1093/jac/dkaa355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。